Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Account Payables: 2022-2025

Historic Change in Account Payables for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $688,000.

  • Day One Biopharmaceuticals' Change in Account Payables rose 120.08% to $688,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 838.24%. This contributed to the annual value of $686,000 for FY2024, which is 70.38% down from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Change in Account Payables stood at $688,000, which was down 73.02% from $2.5 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Change in Account Payables' 5-year high stood at $4.4 million during Q1 2023, with a 5-year trough of -$3.7 million in Q4 2022.
  • For the 3-year period, Day One Biopharmaceuticals' Change in Account Payables averaged around $501,636, with its median value being $245,000 (2024).
  • Data for Day One Biopharmaceuticals' Change in Account Payables shows a peak YoY increase of 2,348.65% (in 2024) and a maximum YoY decrease of 191.91% (in 2024) over the last 5 years.
  • Over the past 4 years, Day One Biopharmaceuticals' Change in Account Payables (Quarterly) stood at -$3.7 million in 2022, then skyrocketed by 78.05% to -$815,000 in 2023, then spiked by 130.06% to $245,000 in 2024, then spiked by 120.08% to $688,000 in 2025.
  • Its last three reported values are $688,000 in Q3 2025, $2.5 million for Q2 2025, and -$722,000 during Q1 2025.